Menu
← Oncology Approval Tracker
FDA DECISION ·
Elahere
mirvetuximab soravtansine-gynx · ImmunoGen (AbbVie)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with FDA test-confirmed FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three systemic regimens.
LAMPGEN ANALYSIS
Why it matters
The randomized MIRASOL results confirmed benefit and supported conversion of the 2022 accelerated indication.
What research teams should watch
Confirm FRα testing and regimen count, and align ophthalmic care and dose modification with the treatment cycle.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Platinum-resistant recurrent diseasePRIMARY RECORDS